




RealRate

PHARMACEUTICAL 2023

Verrica Pharmaceuticals Inc
Rank 121 of 471



RealRate

The First AI Rating Agency

www.realrate.ai

The relative strengths and weaknesses of Verrica Pharmaceuticals Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Verrica Pharmaceuticals Inc compared to the market average is the variable Stockholders Equity, increasing the Economic Capital Ratio by 96% points. The greatest weakness of Verrica Pharmaceuticals Inc is the variable Selling, General and Administrative Expense, reducing the Economic Capital Ratio by 19% points.

The company's Economic Capital Ratio, given in the ranking table, is 338%, being 94% points above the market average of 245%.

Input Variable	Value in 1000 USD
Assets, Current	39,115
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	3,459
Liabilities, Non-Current	1,229
Other Assets	1,719
Other Compr. Net Income	29
Other Expenses	725
Other Liabilities	0
Other Net Income	-3,191
Other Revenues	9,032
Property and Equipment	3,887
Research and Development	12,198
Selling, General and Administrative Expense	17,405

Output Variable	Value in 1000 USD
Assets	44,721
Liabilities	4,688
Expenses	30,328
Revenues	9,032
Stockholders Equity	40,033
Net Income	-24,487
Comprehensive Net Income	-24,472
BaseVar	45,994
ECR before LimitedLiability	254%
Economic Capital Ratio	338%